Latest news with #AdemiFirm
Globe and Mail
a day ago
- Business
- Globe and Mail
Shareholder Alert: The Ademi Firm Investigates Whether Veritex Holdings, Inc. Is Obtaining a Fair Price for Its Public Shareholders
The Ademi Firm is investigating Veritex (NASDAQ: VBTX) for possible breaches of fiduciary duty and other violations of law in its transaction with Huntington . Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, shareholders of Veritex will receive 1.95 shares for each outstanding share of Veritex. Based on Huntington's closing price of $17.39 on July 11, 2025, the consideration implies $33.91 per Veritex share. Veritex insiders will receive substantial benefits as part of change of control arrangements. The transaction agreement unreasonably limits competing transactions for Veritex by imposing a significant penalty if Veritex accepts a competing bid. We are investigating the conduct of the Veritex board of directors, and whether they are fulfilling their fiduciary duties to all shareholders. We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.
Business Wire
a day ago
- Business
- Business Wire
Shareholder Alert: The Ademi Firm Investigates Whether Monogram Technologies Inc. is Obtaining a Fair Price for its Public Shareholders
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Monogram (NASDAQ: MGRM) for possible breaches of fiduciary duty and other violations of law in its transaction with Zimmer Biomet. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, shareholders of Monogram will receive $4.04 per share in cash, representing an equity value of approximately $177 million and an enterprise value of approximately $168 million. The transaction also includes contingent value rights that could provide Monogram shareholders up to an additional $12.37 per share through 2030 if certain product development, regulatory and revenue milestones are achieved. Monogram insiders will receive substantial benefits as part of change of control arrangements. The transaction agreement unreasonably limits competing transactions for Monogram by imposing a significant penalty if Monogram accepts a competing bid. We are investigating the conduct of the Monogram board of directors, and whether they are fulfilling their fiduciary duties to all shareholders. We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.
Business Wire
5 days ago
- Business
- Business Wire
Shareholder Alert: The Ademi Firm Investigates Whether WK Kellogg Co is Obtaining a Fair Price for its Public Shareholders
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating WK Kellogg Co (NYSE: KLG) for possible breaches of fiduciary duty and other violations of law in its transaction with Ferrero. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, shareholders of WK Kellogg Co will receive $23.00 per share in cash, representing a total enterprise value of $3.1 billion. WK Kellogg Co insiders will receive substantial benefits as part of change of control arrangements. The transaction agreement unreasonably limits competing transactions for WK Kellogg Co by imposing a significant penalty if WK Kellogg Co accepts a competing bid. We are investigating the conduct of the WK Kellogg Co board of directors, and whether they are fulfilling their fiduciary duties to all shareholders. We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.
Business Wire
17-06-2025
- Business
- Business Wire
Shareholder Alert: The Ademi Firm Investigates Whether Verve Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Verve (Nasdaq: VERV) for possible breaches of fiduciary duty and other violations of law in its transaction with Eli Lilly. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ or toll-free: 866-264-3995. There is no cost or obligation to you. In the tender offer transaction, shareholders of Verve will receive $10.50 per share in cash (an aggregate of approximately $1.0 billion) payable at closing, plus one non-tradeable contingent value right (CVR) per share that entitles the holder to receive up to an additional $3.00 per share, for a total potential consideration of up to $13.50 per share in cash without interest (an aggregate of up to approximately $1.3 billion). CVR holders would become entitled to receive the contingent payment upon the first patient being dosed with VERVE-102 for ASCVD in a U.S. Phase 3 clinical trial on or prior to the tenth anniversary of closing or termination of the CVR. Verve insiders will receive substantial benefits as part of change of control arrangements. The transaction agreement unreasonably limits competing transactions for Verve by imposing a significant penalty if Verve accepts a competing bid. We are investigating the conduct of the Verve board of directors, and whether they are fulfilling their fiduciary duties to all shareholders. We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.
Business Wire
16-06-2025
- Business
- Business Wire
Shareholder Alert: The Ademi Firm Investigates Whether Cantaloupe, Inc. Is Obtaining a Fair Price for Its Public Shareholders
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Cantaloupe (NASDAQ: CTLP) for possible breaches of fiduciary duty and other violations of law in its transaction with 365 Retail Markets. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ or toll-free: 866-264-3995. There is no cost or obligation to you. In the cash transaction, shareholders of Cantaloupe will receive $11.20 per share, with an equity value of approximately $848 million. Cantaloupe insiders will receive substantial benefits as part of change of control arrangements. The transaction agreement unreasonably limits competing transactions for Cantaloupe by imposing a significant penalty if Cantaloupe accepts a competing bid. We are investigating the conduct of the Cantaloupe board of directors, and whether they are fulfilling their fiduciary duties to all shareholders. We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.
